Sector ratings Lotus Pharmaceutical Co., Ltd.

Equities

End-of-day quote Taiwan S.E. Other stock markets 2025-06-13			5-day change	1st Jan Change
218.50 ^TWD	-2.24%		-7.81%	-18.92%

06-09	Tranche Update on Lotus Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 10, 2025.	CI
05-21	Lotus Pharmaceutical Co., Ltd., Q1 2025 Earnings Call, May 21, 2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	ESG MSCI	Capi.($)
LOTUS PHARMACEUTICAL CO., LTD.	A	1.94B
ELI LILLY AND COMPANY	A	736B
JOHNSON & JOHNSON	A	378B
NOVO NORDISK A/S	AAA	355B
ABBVIE INC.	A	338B
ROCHE HOLDING AG	A	266B
NOVARTIS AG	AA	235B
ASTRAZENECA PLC	AA	232B
MERCK & CO., INC.	A	205B
AMGEN INC.	A	159B
PFIZER, INC.	A	140B
GILEAD SCIENCES, INC.	AAA	137B
SANOFI	BBB	122B
VERTEX PHARMACEUTICALS INCORPORATED	AA	117B
BRISTOL-MYERS SQUIBB COMPANY	A	101B
CHUGAI PHARMACEUTICAL CO., LTD.	AA	85.23B
GSK PLC	AA	83.24B
JIANGSU HENGRUI MEDICINE CO., LTD.	A	49.75B
HALEON PLC	A	48.43B
Average	AA	199.38B
Weighted average by Cap.	AA